Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue

Immunicum AB (publ) (the "Company" or "Immunicum") has, as previously announced, implemented a share issue with preferential rights for the Company's existing shareholders. The newly implemented share issue has entailed a change in number of shares and votes in the Company.

Through the Rights Issue, the number of shares and votes have increased by 20,383,412, which has increased the Company's share capital by SEK 1,019,170.60. As of January 31, 2019, the total share capital in Immunicum amounts to SEK 4,612,876.55 and the total number of shares and votes amount to 92,257,531.

This information is such information that Immunicum AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (Sw. lagen (1991:980) om handel med finansiella instrument). The information was submitted for publication, through the agency of the contact persons set out below, on January 31, 2019, at 8:30 CET.

FOR MORE INFORMATION, PLEASE CONTACT:

Carlos de Sousa, CEO, Immunicum

Telephone: +46 (0) 31 41 50 52

E-mail: info@immunicum.com

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com

ABOUT IMMUNICUM AB (PUBL)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com